{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:22:51Z","timestamp":1787840571132,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The most common clinical indication of aminoglycosides (AG) is the treatment of serious Gram-negative infections. The aim of this study was to evaluate plausible effects of atorvastatin on the biomarkers of acute kidney injury (AKI) in patients receiving amikacin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>In this double-blinded randomized clinical trial, fifty patients (25 in each group) receiving amikacin (15 mg\/kg\/day) were randomly assigned to either atorvastatin (40 mg\/day) or placebo (40 mg\/day) groups for 7 days. Blood urea nitrogen (BUN), serum creatinine (SCr), and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels were measured at days 0, 1, and 7 of amikacin treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During the study period, 4 (8%) patients including two patients in each atorvastatin and placebo group experienced AKI. Urine NGAL\/urine Cr did not change significantly between and within placebo and atorvastatin groups during the study period. Similarly, the mean changes in SCr, BUN, and urine NGAL\/urine Cr values did not differ significantly between and within patients with and without AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our data suggested that the changing pattern of urine NGAL\/urine Cr ratio did not differ significantly between the atorvastatin and placebo groups during the early phase of amikacin treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/1735-1995.202150","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T04:55:24Z","timestamp":1489553724000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Effects of atorvastatin on biomarkers of acute kidney injury in amikacin recipients: A pilot, randomized, placebo-controlled, clinical trial"],"prefix":"10.4103","volume":"22","author":[{"given":"Behrooz","family":"Heydari","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khalili","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Taghi","family":"Beigmohammadi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Intensive Care, Faculty of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Abdollahi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Karimzadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"R1-20250827","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2165\/00003495-199447060-00004","article-title":"Parenteral aminoglycoside therapy. Selection, administration and monitoring","volume":"47","author":"Kumana","year":"1994","journal-title":"Drugs"},{"key":"R2-20250827","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00202170","article-title":"Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety","volume":"48","author":"Gall\u00f8e","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"R3-20250827","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int"},{"key":"R4-20250827","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0306-3623(94)90145-7","article-title":"Influence of iron, deferoxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats","volume":"25","author":"Ben Ismail","year":"1994","journal-title":"Gen Pharmacol"},{"key":"R5-20250827","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0306-3623(95)02032-2","article-title":"Effect of superoxide dismutase treatment on gentamicin nephrotoxicity in rats","volume":"27","author":"Ali","year":"1996","journal-title":"Gen Pharmacol"},{"key":"R6-20250827","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1191\/096032701678766859","article-title":"Effect of dimethyl sulfoxide on gentamicin-induced nephrotoxicity in rats","volume":"20","author":"Ali","year":"2001","journal-title":"Hum Exp Toxicol"},{"key":"R7-20250827","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00925707","article-title":"Role of DL alpha-lipoic acid in gentamicin induced nephrotoxicity","volume":"145","author":"Sandhya","year":"1995","journal-title":"Mol Cell Biochem"},{"key":"R8-20250827","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-2999(01)01130-X","article-title":"Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats","volume":"424","author":"Mazzon","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"R9-20250827","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1211\/002235702760345374","article-title":"Melatonin: Reducing the toxicity and increasing the efficacy of drugs","volume":"54","author":"Reiter","year":"2002","journal-title":"J Pharm Pharmacol"},{"key":"R10-20250827","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.ajkd.2004.08.040","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function","volume":"45","author":"Epstein","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R11-20250827","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/08860220902835863","article-title":"Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways","volume":"31","author":"Ozbek","year":"2009","journal-title":"Ren Fail"},{"key":"R12-20250827","first-page":"1181","article-title":"Simvastatin ameliorates gentamicin-induced renal injury in rats","volume":"22","author":"Jabbari","year":"2011","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"R13-20250827","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2217\/bmm.13.51","article-title":"Clinical use of biomarkers for toxicant-induced acute kidney injury","volume":"7","author":"Pianta","year":"2013","journal-title":"Biomark Med"},{"key":"R14-20250827","first-page":"627","article-title":"Atorvastatin for prevention of Amikacin-induced electrolytes imbalances; a randomized clinical trial","volume":"15","author":"Heydari","year":"2016","journal-title":"Iran J Pharm Res"},{"key":"R15-20250827","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s001340051281","article-title":"Acute renal failure in the ICU: Risk factors and outcome evaluated by the SOFA score","volume":"26","author":"de Mendon\u00e7a","year":"2000","journal-title":"Intensive Care Med"},{"key":"R16-20250827","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3949\/ccjm.69.4.289","article-title":"How to prevent, recognize, and treat drug-induced nephrotoxicity","volume":"69","author":"Guo","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"R17-20250827","doi-asserted-by":"crossref","first-page":"588","DOI":"10.18433\/J3T30F","article-title":"Statins against drug-induced nephrotoxicity","volume":"16","author":"Dashti-Khavidaki","year":"2013","journal-title":"J Pharm Pharm Sci"},{"key":"R18-20250827","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bcp.2009.09.021","article-title":"Statins inhibit aminoglycoside accumulation and cytotoxicity to renal proximal tubule cells","volume":"79","author":"Antoine","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"R19-20250827","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bpa.2011.06.004","article-title":"Renal injury in the elderly: Diagnosis, biomarkers and prevention","volume":"25","author":"Haase","year":"2011","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"R20-20250827","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/apha.12054","article-title":"Neutrophil gelatinase-associated lipocalin: Pathophysiology and clinical applications","volume":"207","author":"Singer","year":"2013","journal-title":"Acta Physiol (Oxf)"},{"key":"R21-20250827","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00280-015-2880-y","article-title":"Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients","volume":"76","author":"Shinke","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"R22-20250827","doi-asserted-by":"crossref","first-page":"c154","DOI":"10.1159\/000312879","article-title":"Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: A pilot prospective case-control study","volume":"115","author":"Gaspari","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"R23-20250827","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.kjms.2012.10.004","article-title":"Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels","volume":"29","author":"Lin","year":"2013","journal-title":"Kaohsiung J Med Sci"},{"key":"R24-20250827","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5935\/0101-2800.20140041","article-title":"Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancer","volume":"36","author":"Peres","year":"2014","journal-title":"J Bras Nefrol"},{"key":"R25-20250827","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/ptr.5345","article-title":"Effect of silymarin administration on cisplatin nephrotoxicity: Report from a pilot, randomized, double-blinded, placebo-controlled clinical trial","volume":"29","author":"Shahbazi","year":"2015","journal-title":"Phytother Res"},{"key":"R26-20250827","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1128\/AAC.00280-15","article-title":"Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity","volume":"59","author":"Sirijatuphat","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20250827","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000093961","article-title":"Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions","volume":"26","author":"Bachorzewska-Gajewska","year":"2006","journal-title":"Am J Nephrol"},{"key":"R28-20250827","first-page":"703","article-title":"Administration of higher doses of amikacin in early stages of sepsis in critically ill patients","volume":"52","author":"Najmeddin","year":"2014","journal-title":"Acta Med Iran"}],"container-title":["Journal of Research in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01222967-201722000-00039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:25:14Z","timestamp":1787837114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01222967-201722000-00039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/1735-1995.202150","relation":{},"ISSN":["1735-1995","1735-7136"],"issn-type":[{"value":"1735-1995","type":"print"},{"value":"1735-7136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"2016-10-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}